Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the dunning rat prostate model system

Urology

Volumn 50, Issue 6, 1997, Pages 999-1006

  Getzenberg, Robert H ^a   Light, Benjamin W ^b   Lapco, Paul E ^b   Konety, Badrinath R ^b   Nangia, Ajay K ^b   Acierno, James S ^b   Dhir, Rajiv ^b   Shurin, Zoya ^b   Day, Roger S ^b   Trump, Donald L ^b   Johnson, Candace S ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCITRIOL RECEPTOR; VITAMIN D;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MORTALITY; CANCER RISK; CELL DIFFERENTIATION; CELL PROLIFERATION; CLONOGENESIS; DISEASE MODEL; DISEASE SEVERITY; MALE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE DISEASE; RAT; RISK FACTOR; TUMOR GROWTH; TUMOR VOLUME;

ADENOCARCINOMA; ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; CALCITRIOL; CELL CYCLE; DEPRESSION, CHEMICAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; LUNG NEOPLASMS; MALE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; RATS; RATS, INBRED STRAINS; TUMOR CELLS, CULTURED;

EID: 0031463720     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00408-1     Document Type: Article

References (28)

1. Schwartz GG, and Hulka BS: Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10: 1307-1311, 1990.
2. Hanchette CL, and Schwartz GG: Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 70: 2861-2869, 1992.
3. 3 analog in a squamous cell carcinoma model system. Mol Cell Diff 3: 31-50, 1995.
4. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, and Johnson CS: Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 57: 3759-3764, 1997.
5. Konety BR, Schwartz GG, Acierno JS Jr, Becich MJ, and Getzenberg RH: The role of vitamin D in normal prostatic growth and differentiation. Cell Growth Differ 7: 1563-1570, 1996.
6. 3. Cancer Res 52: 515-520, 1992.
7. 3 receptors and actions in human prostate cancer cell lines. Endocrinol 132: 1952-1960, 1993.
8. 3 on primary cultures of human prostatic cells. Cancer Res 54: 805-810, 1994.
9. Isaacs JT, Isaacs WB, Feitz WF, and Scheres J: Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9: 261-281, 1986.
10. Vindelov LL, Christensen IJ, and Nissen NI: A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323-327, 1983.
11. Johnson CS, Chang MJ, Yu WD, Modzelewski RA, Grandis JR, Vlock DR, and Furmanski P: Synergistic enhancement of interleukin-1alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice. Cancer Chemother Pharmacol 32: 339-346, 1993.
12. Teitz NW: Blood gases and electrolytes, in Fundamentals of Clinical Chemistry, 2nd ed. Philadelphia, WB Saunders, 1976, p 980.
13. Davies M: High-dose vitamin D therapy: indications, benefits and hazards, in Walter P, Brubacher G, and Stahelin H (Eds): Elevated Dosages of Vitamins. New York, Hans Huber, 1989, pp 81-86.
14. Schwartz GG: Correspondence re: EH Corder et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 3: 183-184, 1994.
15. Bikle DD, and Pillai S: Vitamin D, calcium and epidermal differentiation. Endocr Rev 14: 3-19, 1993.
16. Reichel H, Koeffler HP, and Norman AW: The role of the vitamin D endocrine system in health and disease. N Engl J Med 320: 980-991, 1989.
17. Bouillon R, Okamura WH, and Norman AW: Structure function relationships in the vitamin D endocrine system. Endocr Rev 16: 200-257, 1995.
18. Zhou JY, Norman AW, Lubbert M, Collins ED, Uskokovic MR, and Koffler HP: Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone calcium mobilization. Blood 74: 82-93, 1989.
19. Colston KW, Chander SK, Mackay AG, and Coombes RC: Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 44: 693-702, 1993.
20. 3. Cancer Res 54: 4057-4064, 1994.
21. 3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J Cell Biol 98: 391-398, 1984.
22. Schwartz GG, Oeler TA, Uskokovic MR, and Bahnson RR: Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res 14: 1077-1081, 1994.
23. Lucia MS, Anzano MA, Slayter MV, Anver MR, Green DM, Shrader MW, Logsdon DL, Driver CL, Brown CC, Peer CW, et al: Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5331, for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Cancer Res 55: 5621-5627, 1995.
24. Musgrove EA, and Sutherland RL: Cell cycle control by steroid hormones. Semin Cancer Biol 5: 381-389, 1994.
25. 3. Cancer Res 45: 3898-3905, 1985.
26. 3. Cell Prolif 27: 37-46, 1994.
27. 3 in HL60 cells. Cancer Res 56: 264-267, 1996.
28. 3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 55: 2822-2830, 1995.